Korro Bio develops RNA editing medicines for rare and common diseases, with its programs still in research or preclinical stages. KRRO reports earnings on Wed, Nov 11, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 20 | HC Wainwright & Co. | Reiterated | Buy | |
| May 19 | HC Wainwright & Co. | Maintained | Buy | |
| May 18 | Citigroup | Initiated | Buy | |
| Mar 13 | Raymond James | Upgrade | Buy |
Seasonality
How KRRO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.
Whale Options Flow
90DNo whale options trades in KRRO in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KRRO is in one of them and how their past KRRO trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered KRRO in an article yet. Here's the latest on the wider market.
About Korro Bio
Korro Bio is a biopharmaceutical company based in Cambridge, Massachusetts, that is developing a new class of genetic medicines that edit RNA rather than DNA. Its approach uses engineered oligonucleotides that work with a natural cell process to make precise, temporary changes to proteins. The company aims to treat both rare and widely prevalent diseases, including urea cycle disorders, liver conditions and ALS, but its programs are still in research or preclinical development.
- Headquarters
- Cambridge, MA